Phillip Saccone

Publications (3)8.63 Total impact

• Article: Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health

  Perrine Roux, Claudia Tindall, Lionel Fugon, Janet Murray, Suzanne K. Vosburg, Phillip Saccone, Maria A. Sullivan, Jeanne M. Manubay, Ziva D. Cooper, Jermaine D. Jones, Richard W. Foltin, Sandra D. Comer
  Addiction. 03/2012;
• Article: Impact of in‐patient research participation on subsequent heroin use patterns: implications for ethics and public health

  Perrine Roux, Claudia Tindall, Lionel Fugon, Janet Murray, Suzanne K. Vosburg, Phillip Saccone, Maria A. Sullivan, Jeanne M. Manubay, Ziva D. Cooper, Jermaine D. Jones, Richard W. Foltin, Sandra D. Comer
  [show abstract] [hide abstract]
  ABSTRACT: Aims Research on drug dependence often involves the administration of drugs of abuse to experienced drug users under controlled laboratory conditions. The primary objective of this study was to assess whether participation in such research alters the frequency of heroin use by non-treatment-seeking opioid-dependent volunteers after study completion.Design Data were examined from four in-patient studies involving controlled opioid administration.Setting Substance Use Research Center at Columbia University, New York State Psychiatric Institute.Participants Sixty-nine heroin-dependent volunteers.Measurements Participants' self-reported heroin use prior to and 1 month after study participation was compared using a Wilcoxon test. Because a number of participants reported that they had stopped using heroin, a logistic regression was used to identify correlates of heroin cessation 1 month after study completion.Findings One hundred and one participants entered laboratory studies and 69 completed them. Self-reported heroin use significantly decreased 1 month after study participation [1.7 (±2.0) bags per day] compared to baseline [6.8 (±4.2) bags per day], P < 0.001 among the 69 completers. In addition, 42% of the completers were heroin-abstinent 1 month after study completion. Being African American, having a history of opioid dependence treatment, reporting heavier heroin use at baseline and a longer history of heroin use were correlated with cessation of heroin use.Conclusions Participation in opioid administration studies does not increase subsequent heroin use and for some individuals leads to accessing opioid dependence treatment and cessation of heroin use in the short term.
  Addiction 02/2012; 107(3):642 - 649. · 4.31 Impact Factor
• Article: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

  Sandra D Comer, Maria A Sullivan, Suzanne K Vosburg, Jeanne Manubay, Leslie Amass, Ziva D Cooper, Phillip Saccone, Herbert D Kleber
  [show abstract] [hide abstract]
  ABSTRACT: Sublingual buprenorphine is an effective maintenance treatment for opioid dependence, yet intravenous buprenorphine misuse occurs. A buprenorphine/naloxone formulation was developed to mitigate this misuse risk. This randomized, double-blind, cross-over study was conducted to assess the intravenous abuse potential of buprenorphine/naloxone compared with buprenorphine in buprenorphine-maintained injection drug users (IDUs). Intravenous heroin users (n = 12) lived in the hospital for 8-9 weeks and were maintained on each of three different sublingual buprenorphine doses (2 mg, 8 mg, 24 mg). Under each maintenance dose, participants completed laboratory sessions during which the reinforcing and subjective effects of intravenous placebo, naloxone, heroin and low and high doses of buprenorphine and buprenorphine/naloxone were examined. Every participant received each test dose under the three buprenorphine maintenance dose conditions. Intravenous buprenorphine/naloxone was self-administered less frequently than buprenorphine or heroin (P < 0.0005). Participants were most likely to self-administer drug intravenously when maintained on the lowest sublingual buprenorphine dose. Subjective ratings of 'drug liking' and 'desire to take the drug again' were lower for buprenorphine/naloxone than for buprenorphine or heroin (P = 0.0001). Participants reported that they would pay significantly less money for buprenorphine/naloxone than for buprenorphine or heroin (P < 0.05). Seven adverse events were reported; most were mild and transient. These data suggest that although the buprenorphine/naloxone combination has intravenous abuse potential, that potential is lower than it is for buprenorphine alone, particularly when participants received higher maintenance doses and lower buprenorphine/naloxone challenge doses. Buprenorphine/naloxone may be a reasonable option for managing the risk for buprenorphine misuse during opioid dependence treatment.
  Addiction 04/2010; 105(4):709-18. · 4.31 Impact Factor